We are live on
!
Find out more
SAM
Sectoral Asset Management Portfolio holdings
AUM
$121M
1-Year Est. Return
73.47%
This Fund
S&P 500
This Quarter
Est. Return
-5.4%
1 Year Est. Return
+73.47%
3 Year Est. Return
+165.77%
5 Year Est. Return
+169.27%
10 Year Est. Return
+1,136.49%
AUM
$496M
AUM Growth
-$67M
(-12%)
Cap. Flow
-$12.4M
Cap. Flow
% of AUM
-2.49%
Top 10 Holdings %
Top 10 Hldgs %
25.38%
Holding
128
New
22
Increased
39
Reduced
44
Closed
16
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Icon
ICLR
|
+$7.57M |
| 2 |
iRhythm Holdings
IRTC
|
+$6.12M |
| 3 |
Travere Therapeutics
TVTX
|
+$5.83M |
| 4 |
Lantheus
LNTH
|
+$5.59M |
| 5 |
Alkermes
ALKS
|
+$5.45M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
OCDX
Ortho Clinical Diagnostics Holdings plc Ordinary Shares
OCDX
|
+$12.4M |
| 2 |
TPTX
Turning Point Therapeutics, Inc. Common Stock
TPTX
|
+$8.48M |
| 3 |
Health Catalyst
HCAT
|
+$6.58M |
| 4 |
Thermo Fisher Scientific
TMO
|
+$5.99M |
| 5 |
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
+$5.45M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 95.62% |
| 2 | Industrials | 4.38% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
Humana
HUM
$43.4B
| $6.66M | 1.34% |
14,225
+2,700
| +23% | +$1.2M |
|
27
Tandem Diabetes Care
TNDM
$1.24B
| $6.26M | 1.26% |
105,763
+26,175
| +33% | +$2.15M |
|
28
AbbVie
ABBV
$471B
| $6.17M | 1.24% |
40,300
-20,000
| -33% | -$3.06M |
|
29
Abbott
ABT
$190B
| $6.17M | 1.24% |
56,748
-2,750
| -5% | -$312K |
|
|
FOLD
30
DELISTED
Amicus Therapeutics
FOLD
| $6.02M | 1.21% |
560,882
-62,900
| -10% | -$518K |
|
31
Eli Lilly
LLY
$1.09T
| $5.97M | 1.2% |
18,415
-10,050
| -35% | -$3.02M |
|
32
Denali Therapeutics
DNLI
$3.79B
| $5.95M | 1.2% |
202,100
-5,000
| -2% | -$131K |
|
|
SWAV
33
DELISTED
Shockwave Medical, Inc. Common Stock
SWAV
| $5.93M | 1.19% |
31,000
-4,000
| -11% | -$706K |
|
|
34
Lantheus
LNTH
$6.51B
| $5.86M | 1.18% |
+88,687
| New | +$5.59M |
|
|
SGEN
35
DELISTED
Seagen Inc. Common Stock
SGEN
| $5.76M | 1.16% |
32,530
-8,600
| -21% | -$1.24M |
|
36
Halozyme
HALO
$9.87B
| $5.74M | 1.16% |
130,400
+4,400
| +3% | +$190K |
|
|
37
Alkermes
ALKS
$8.1B
| $5.65M | 1.14% |
+189,650
| New | +$5.45M |
|
|
38
Travere Therapeutics
TVTX
$5.24B
| $5.62M | 1.13% |
+232,000
| New | +$5.83M |
|
39
Treace Medical Concepts
TMCI
$256M
| $5.4M | 1.09% |
376,678
+165,654
| +79% | +$2.79M |
|
40
Tenet Healthcare
THC
$22.2B
| $5.33M | 1.08% |
101,500
-41,500
| -29% | -$2.89M |
|
41
Merck
MRK
$324B
| $5.26M | 1.06% |
57,750
| – | – |
|
|
ITCI
42
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $5.18M | 1.04% |
+90,800
| New | +$5.15M |
|
|
RXDX
43
DELISTED
Prometheus Biosciences, Inc. Common Stock
RXDX
| $4.87M | 0.98% |
+172,505
| New | +$5M |
|
44
Boston Scientific
BSX
$69.1B
| $4.73M | 0.95% |
126,976
+24,250
| +24% | +$987K |
|
|
BLU
45
DELISTED
BELLUS Health Inc.
BLU
| $4.63M | 0.93% |
501,413
-289,224
| -37% | -$2.37M |
|
|
MRTX
46
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $4.61M | 0.93% |
68,613
+8,776
| +15% | +$558K |
|
47
Fate Therapeutics
FATE
$269M
| $4.54M | 0.91% |
183,000
-10,160
| -5% | -$280K |
|
48
STAAR Surgical
STAA
$1.19B
| $4.43M | 0.89% |
62,500
| – | – |
|
|
IMGN
49
DELISTED
Immunogen Inc
IMGN
| $4.23M | 0.85% |
940,244
+61,400
| +7% | +$267K |
|
|
CNVY
50
DELISTED
Convey Health Solutions Holdings, Inc.
CNVY
| $4.16M | 0.84% |
400,000
-67,793
| -14% | -$421K |
|
Similar funds
RIP
LFWA
CF
WIM
MW
AFC
AAA
TGM
Sectoral Asset Management's Q2 2022 Portfolio in Review
As of Q2 2022, Sectoral Asset Management held 128 positions worth $496M, down 12% from $563M the previous quarter. Its ten largest holdings account for 25% of the portfolio.
Sectoral Asset Management's Q2 2022 filing shows 22 new, 39 increased, 44 reduced and 16 closed positions. Its largest new stake was Travere Therapeutics: 232,000 shares worth $5.62M. The largest sale was Ortho Clinical Diagnostics Holdings plc Ordinary Shares, an estimated $12.4M.
By sector, the portfolio is most concentrated in Healthcare at 96% of assets, down from 96% a quarter earlier, followed by Industrials.
- Sectoral Asset Management's largest Q2 2022 buy was Travere Therapeutics: 232,000 shares worth $5.62M.
- Sectoral Asset Management added most to Icon in Q2 2022, an estimated $7.57M increase.
- Sectoral Asset Management's biggest Q2 2022 reduction was Turning Point Therapeutics, Inc. Common Stock, cutting an estimated $8.48M.
- Sectoral Asset Management fully exited Ortho Clinical Diagnostics Holdings plc Ordinary Shares in Q2 2022, selling an estimated $12.4M.
- Sectoral Asset Management's ten largest holdings make up 25% of its $496M portfolio in Q2 2022.
- Sectoral Asset Management opened 22 new positions and closed 16 in Q2 2022.
- Sectoral Asset Management's portfolio value fell 12% quarter-over-quarter to $496M.
Based on Sectoral Asset Management's 13F filing for Q2 2022, filed 15 Aug 2022.